Anticancer Non-narcotic Opium Alkaloid Papaverine Suppresses Human Glioblastoma Cell Growth.
Animals
Antineoplastic Agents
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Brain Neoplasms
/ drug therapy
Cell Line, Tumor
Cell Proliferation
/ drug effects
Glioblastoma
/ drug therapy
HMGB1 Protein
/ antagonists & inhibitors
Humans
Male
Mice
Mice, Inbred BALB C
Mice, Nude
Papaverine
/ therapeutic use
Radiation Tolerance
/ drug effects
Receptor for Advanced Glycation End Products
/ antagonists & inhibitors
Temozolomide
/ therapeutic use
Tumor Burden
/ drug effects
Xenograft Model Antitumor Assays
GBM
Papaverine
anti-cancer effect
radiosensitization
temozolomide
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
26
10
2019
revised:
11
11
2019
accepted:
12
11
2019
entrez:
8
12
2019
pubmed:
8
12
2019
medline:
18
12
2019
Statut:
ppublish
Résumé
Glioblastoma (GBM) is the most aggressive type of primary malignant brain tumour. The interaction between high-mobility group box 1 (HMGB1) and receptor for advanced glycation end-products (RAGE) is important for tumour cell growth. Previously, we identified an anticancer candidate, papaverine, that inhibited the HMGB1-RAGE interaction. Our study assessed the anticancer effects of papaverine alone or in combination with temozolomide on U87MG and T98G human GBM cells using clonogenicity assays, as well as in a U87MG xenograft mouse model. The radiosensitizing efficacy of papaverine was measured based on the clonogenicity of T98G cells. Papaverine significantly inhibited the clonogenicity of U87MG and T98G cells. Compared with single treatment, the combination of papaverine and temozolomide more highly suppressed the clonogenicity of T98G cells and delayed tumour growth in the U87MG xenograft mouse model. Furthermore, papaverine increased the radiosensitivity of T98G cells. Papaverine is a potential anticancer drug in GBM treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Glioblastoma (GBM) is the most aggressive type of primary malignant brain tumour. The interaction between high-mobility group box 1 (HMGB1) and receptor for advanced glycation end-products (RAGE) is important for tumour cell growth. Previously, we identified an anticancer candidate, papaverine, that inhibited the HMGB1-RAGE interaction.
MATERIALS AND METHODS
METHODS
Our study assessed the anticancer effects of papaverine alone or in combination with temozolomide on U87MG and T98G human GBM cells using clonogenicity assays, as well as in a U87MG xenograft mouse model. The radiosensitizing efficacy of papaverine was measured based on the clonogenicity of T98G cells.
RESULTS
RESULTS
Papaverine significantly inhibited the clonogenicity of U87MG and T98G cells. Compared with single treatment, the combination of papaverine and temozolomide more highly suppressed the clonogenicity of T98G cells and delayed tumour growth in the U87MG xenograft mouse model. Furthermore, papaverine increased the radiosensitivity of T98G cells.
CONCLUSION
CONCLUSIONS
Papaverine is a potential anticancer drug in GBM treatment.
Identifiants
pubmed: 31810939
pii: 39/12/6743
doi: 10.21873/anticanres.13889
doi:
Substances chimiques
Antineoplastic Agents
0
HMGB1 Protein
0
HMGB1 protein, human
0
Receptor for Advanced Glycation End Products
0
Papaverine
DAA13NKG2Q
Temozolomide
YF1K15M17Y
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6743-6750Informations de copyright
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.